Previous Article | Next Article ![]()
Mol. Cell. Biol., 04 1997, 2038-2047, Vol 17, No. 4
YH Lee, SC Williams, M Baer, E Sterneck, FJ Gonzalez and PF Johnson
The rat CYP2D5 P-450 gene is activated in the liver during postnatal
development. We previously showed that liver-specific transcription of the
CYP2D5 gene is dictated by a proximal promoter element, termed 2D5, that is
composed of a binding site for Sp1 or a related factor, and an adjacent
cryptic C/EBP (CCAAT/enhancer-binding protein) site. Despite the fact that
both C/EBP alpha and C/EBP beta are expressed abundantly in liver, only
C/EBP beta is capable of stimulating the 2D5 promoter in HepG2
hepatocarcinoma cells. In addition, activation of the 2D5 promoter by C/EBP
beta is completely dependent on the presence of the Sp1 site. Domain switch
experiments reveal that C/EBP beta proteins containing either the leucine
zipper or the activation domain of C/EBP alpha are unable to stimulate the
2D5 promoter yet are fully capable of transactivating an artificial
promoter bearing a high-affinity C/EBP site. Thus, the leucine zipper and
the activation domain of C/EBP beta are absolutely required to support
transactivation of the 2D5 promoter. Using Drosophila cells that lack
endogenous Sp1 activity, we show that the serine/threonine- and
glutamine-rich activation domains A and B of Sp1 are required for efficient
cooperatively with C/EBP beta. Furthermore, analysis of c/ebp
beta-deficient mice shows that mutant animals are defective in expression
of a murine CYP2D5 homolog in hepatic cells, confirming the selective
ability of C/EBP beta to activate this liver-specific P-450 gene in vivo.
Our findings illustrate that two members of a transcription factor family
can achieve distinct target gene specificities through differential
interactions with a cooperating Sp1 protein.
Copyright © 1997, American Society for Microbiology
The ability of C/EBP beta but not C/EBP alpha to synergize with an Sp1 protein is specified by the leucine zipper and activation domain
Laboratory of Molecular Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|